Illumina

Meet the MiSeq i100 Series – the new standard in sequencing simplicity with a 3-step setup, onboard DRAGEN analysis, and same-day results to accelerate genomic discovery and insights: https://bit.ly/4eTqugz

Join us at #AMPath24 to discuss the latest research and growing evidence for the clinical utility of CGP, as well as challenges in precision medicine implementation. On Thursday, we will unveil plans for our newest cancer research assay, TruSight Oncology 500 v2, in a spotlight presentation on the TruSight Oncology portfolio and its role in enabling adoption of CGP. Stop by our booth to learn more!

Innovation doesn’t happen overnight, it’s often the result of relentless customer focus by experts like Dorothea Agius and Joe Cottrell on the Systems Integration team. By starting with feedback from customers, the team was able to prioritize applications and test the MiSeq i100 Series with their most adventurous research ideas in mind. Learn how Joe, Dorothea, and team brought together the best elements of Illumina sequencing technology to create a powerful, user-friendly platform for researchers everywhere: https://bit.ly/4hRrT9E

Eric Kelsic and his team are driven by one thing: Accelerating drug discovery. Hear how Dyno Therapeutics is finding ways to keep people healthier, longer with the help of Illumina technology.

“These results further illustrate the paradigm shift in clinical practice in oncology. Patients are seeing better outcomes from precision treatments based on a tumor’s molecular profile compared to conventional approaches used to treat cancer.” – Swaroop Aradhya, VP of Medical and Clinical Affairs at Illumina. Powerful study of CGP, in partnership with Providence and Microsoft Research, published today in the Journal of Clinical Oncology. Congratulations to John Fox, Bela Bapat, Pratheesh Sathyan PhD and the many team members who contributed to this important work over several years.

How do some cancers become more aggressive than others? Luigi Mancinelli, PhD and his team at the University of Pittsburg are using the NovaSeq X Plus and Partek Flow to pinpoint gene activity that may drive osteosarcoma metastasis. By targeting these genetic markers, they hope to block the tumor’s ability to develop metastasis and bring new hope to patients. Learn more about their critical work: https://bit.ly/3Z4FW4k

That’s a wrap on #ASHG24. The conference was an incredible opportunity to connect with our customers and hear about the latest advancements in genomics (and beyond!). Together, we reviewed our innovation roadmap, shared preliminary data highlighting the impact of these developments, and introduced customers to the MiSeq i100 Series for the very first time. From constellation mapped read technology to proteomics, single cell, and bioinformatics, we continue to partner with our customers to build the solutions that meet their needs. For more on our latest developments and partnerships: https://lnkd.in/gpHz9GJg

This Veteran’s Day marks the 4th year we have been recognized as a?Best for Vets Employer?by Military Times. We are honored to be included again, but we know the credit goes to our employees who create the inclusive workplace we strive for every day and to the veterans who choose to work at Illumina. A special thank you to all our U.S.?veteran employees for their service and to the iSERVED employee resource group for fostering community through events like flag-raising ceremonies, volunteer activities, and career discussions.

It has been an inspiring few days spent at #ASHG24 with the Illumina team and so many of our customers and partners from across the #genomics industry. Especially pleased to hear all the positive feedback and excitement about our product pipeline, which includes a constellation map read technology, protein prep solution, and a new single-cell analysis solution from Fluent BioSciences Inc.. At Illumina, we are committed to making next generation sequencing (NGS) easier and more accessible, fueling our #mission to improve human health by unlocking the power of the genome. Thank you to ASHG CEO Amanda P. and her entire team for hosting such a great event.?

Our recent acquisition of Fluent BioSciences is set to transform single-cell research. In our latest article, Cande Rogert and Soroush Zarandi, PhD, MBA discuss how PIPseq V simplifies workflows and brings high-throughput applications to every lab. Dive into the details and see how we’re making cutting-edge technology accessible to all: https://bit.ly/4f8rBcL. And if you’re attending #ASHG24, don’t miss our talk on the power of PIPseq V in scRNA-Seq!